Correction to: Leukemia https://doi.org/10.1038/s41375-021-01157-w, published online 15 February 2021
Following the publication of this article, the authors noted an error in the data reported.
One patient in the AML-D11 study (showing negativity for both FCM-MRD and GATA1-MRD) was incorrectly reported dead after relapse following a data input error. After re-confirming the survival data for all other patients, the dataset has been updated and results are as follows.
The number of patients who relapsed was decreased from 7 to 6.
The 3-year event-free survival (EFS) and overall survival (OS) rates in the entire population (n = 78) were 88.5 and 91.0%.
The 3-year EFS and OS rates in the SR patients (n = 76) were 90.8 and 93.4%.
The 3-year EFS and OS rates were 95.0 and 96.7% in the FCM-MRD-negative population, and 60.0 and 80.0% in the positive population.
Three-year EFS and OS rates were both 98.1% in the GATA1-MRD-negative population, and 57.1 and 71.4% in the positive population.
The adjusted hazard ratios for the association of FCM-MRD with EFS and OS were 14.67 (95% CI, 2.00–107.79; p = 0.01) and 13.48 (0.81–224.27; p = 0.07), respectively, while multivariate analysis of GATA1-MRD did not converge in the updated dataset due to the limited number of events in the GATA1-MRD-negative population.
The conclusions of the article remain unchanged.
About this article
Cite this article
Taga, T., Tanaka, S., Hasegawa, D. et al. Correction to: Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome. Leukemia (2021). https://doi.org/10.1038/s41375-021-01397-w